The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant and Dose-Dependent Expression of Dystrophin in Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen

AVI BioPharma, Inc. AVII today announced that data published in The Lancet from a Phase 1b/2 study of eteplirsen, the Company's exon-skipping therapy for the treatment of Duchenne muscular dystrophy, demonstrate that the treatment was well tolerated and was shown to induce statistically significant and dose-dependent improvements in dystrophin expression in patients. DMD is a genetic muscle wasting disease caused by the absence of functional dystrophin, an essential muscle protein.